Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan

References

• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(5):706–720. doi: 10.1093/annonc/mdz056.
   PubMed Web of Science ®Google Scholar
• Marugame T, Matsuda T. Comparison of time trends in kidney cancer incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents, vols IV-VIII. Jpn J Clin Oncol. 2008;38(7):508–509. doi: 10.1093/jjco/hyn060.
   PubMedGoogle Scholar
• Gangadaran SGD. Current management options in metastatic renal cell cancer. Oncol Rev. 2017;11(2):339. doi: 10.4081/oncol.2017.339.
   PubMedGoogle Scholar
• Japanese Urological Association. Clinical practice guideline for renal cancer (revision of 2017 guidelines) 2017 [September 2020]. Available from: https://www.urol.or.jp/lib/files/other/guideline/33_renal_cancer_2017_rev2019.pdf.
   Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927. doi: 10.1016/S1470-2045(16)30107-3.
   PubMed Web of Science ®Google Scholar
• Chen RC, Choueiri TK, Feuilly M, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2020;126(24):5311–5318. doi: 10.1016/j.ejca.2018.02.012.
   Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823. doi: 10.1056/NEJMoa1510016.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018;118(9):1176–1178. doi: 10.1038/s41416-018-0061-6.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Tatsugami K, Nakaigawa N, et al. Cabozantinib in advanced renal cell carcinoma: a phase II, open-label, single-arm study of Japanese patients. Int J Urol. 2020;27(11):952–959. doi: 10.1111/iju.14329.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Komoto S, Shiroiwa T, et al. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43–51. doi: 10.1016/j.jval.2019.10.005.
   PubMed Web of Science ®Google Scholar
• CORE2 HEALTH (C2H). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Version 2.0 approved by CSIMC on 20th February, 2019.
   Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials–extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–754. doi: 10.1177/0272989X12472398.
   PubMed Web of Science ®Google Scholar
• Ikeda S. Developing a Japanese version of the EQ-5D-5L value set. J Public Health. 2015;64(1):47–55.
   Google Scholar
• e-Stat portal site of official statistics of Japan. Statistics of Japan. 2020;8. Available from: https://www.e-stat.go.jp/en/
   Google Scholar
• National Institute for Health and Care Excellence. Pazopanib for the first-line treatment of advanced renal cell carcinoma: Technology appraisal guidance. [TA215]. 2013. Available from: https://www.nice.org.uk/guidance/ta215.
   Google Scholar
• National Institute for Health and Care Excellence. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment: technology appraisal guidance [TA333] 2015. Available from: https://www.nice.org.uk/guidance/ta333.
   Google Scholar
• National Institute for Health and Care Excellence. Nivolumab for previously treated advanced renal cell carcinoma: technology appraisal guidance [TA417]. 2016. Available from: https://www.nice.org.uk/guidance/ta417.
   Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772. doi: 10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kudo M, Izumi N, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019;54(6):558–570. doi: 10.1007/s00535-019-01554-0.
   PubMed Web of Science ®Google Scholar
• Thom H. Deterministic and probabilistic analysis of a simple Markov model: how different could they be? Appl Health Econ Health Policy. 2022;20(3):447–449. doi: 10.1007/s40258-021-00700-1.
   PubMed Web of Science ®Google Scholar
• Xie X, Yeung MW, Wang Z, et al. Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model. Expert Rev Pharmacoecon Outcomes Res. 2020;20(2):169–175. doi: 10.1080/14737167.2019.1615886.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 4th Edition. [updated March 2017]. Available from: https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition
   Google Scholar
• National Institute for Health and Care Excellence. NICE health technology evaluations: the manual [updated 31 January 2022]. Available from: https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation
   Google Scholar
• National Institute for Health and Care Excellence. Cabozantinib for previously treated advanced renal cell carcinoma: single Technology Appraisal [ID931] 2017 cited 2020 October 8]. Available from: https://www.nice.org.uk/guidance/ta463/documents/committee-papers.
   Google Scholar
• ClinicalTrials.gov. NCT03339219: a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma 2017 [cited 2020 October 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT03339219.
   Google Scholar
• JMDC. JMDC claims database. [cited 2020 October 8]. Available from: https://www.jmdc.co.jp/en/jmdc-claims-database.
   Google Scholar
• National Institute for Health and Care Excellence. Cabozantinib for previously treated advanced renal cell carcinoma Technology appraisal guidance [TA463 ]/. 2017. Available from: https://www.nice.org.uk/guidance/ta463.
   Google Scholar
• National Institute for Health and Care Excellence. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma: technology appraisal guidance [TA498] 2018. Available from: https://www.nice.org.uk/guidance/ta498.
   Google Scholar
• National Institute for Health and Care Excellence. Everolimus for advanced renal cell carcinoma after previous treatment: technology appraisal guidance [TA432] 2017. Available from: https://www.nice.org.uk/guidance/ta432.
   Google Scholar
• National Institute for Health and Care Excellence. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma: technology appraisal guidance [TA178]. 2009. Available from: https://www.nice.org.uk/guidance/ta178.
   Google Scholar
• Coyle D, Haines A, Lee K. Extrapolating clinical evidence within economic evaluations. CJHT. 2023;3(5):1–21. doi: 10.51731/cjht.2023.649.
   Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939. doi: 10.1016/S0140-6736(11)61613-9.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi: 10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–1296. doi: 10.1016/j.ejca.2012.12.010.
   PubMed Web of Science ®Google Scholar